Lipids & metabolic liver disease
Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial
Primary result · Change in absolute % IHL by 1H-MRSResult — go to the resultNet mean treatment effect −8.9 % 95% CI −14.5 to −3.3%Authors' conclusion
GH administration reduces hepatic steatosis in adults with overweight/obesity and NAFLD without worsening glycemic measures. The GH/IGF-1 axis may lead to future therapeutic targets for NAFLD.
Study context
- Population
- Adults aged 18 to 65 years with BMI ≥25 kg/m² and nonalcoholic fatty liver disease (NAFLD) without diabetes41 completers
- Participants
- 53 adults
- Comparison
- Low-dose daily subcutaneous growth hormone (GH) vs placebo
- GHn = 27
- Placebon = 26reference
- Primary endpoint
- Intrahepatic lipid content (IHL) by proton magnetic resonance spectroscopy (1H-MRS)
- Follow-up
- 6 months
Methodological detailsdouble-blind, placebo-controlled, 6-month
- Double-blind
- Placebo-controlled
- 6-month
Primary result
Change in absolute % IHL by 1H-MRS
Net mean treatment effect
−8.9 %
95% CI −14.5 to −3.3%
P = 0.009
Change by group
GH
−5.2
mean · SD 10.5 · %
Placebo
3.8
mean · SD 6.9 · %
As reported in the abstract
Further findings
- No significant differences in change in glycemic measures or insulin resistance between GH and placebo
Safety
Lower extremity edema (non-clinically significant)
P = 0.02
Lower extremity edema (non-clinically significant)
- All other side effects similar between groups
Discontinuations due to worsening glycemic status
- No study discontinuations due to worsening of glycemic status
Original publication
Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial. J Clin Endocrinol Metab. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →